Related Experiment Video
Updated: Mar 6, 2026
The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
Published on: June 30, 2014
Pediatric multiple sclerosis
Anusha K Yeshokumar1, Sona Narula, Brenda Banwell
1Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Insights
Pediatric multiple sclerosis (MS) involves genetic and environmental factors, impacting children under 18. Understanding these risks improves treatment and quality of life for young MS patients.
Area of Science:
- Neurology
- Immunology
- Epidemiology
Background:
- Pediatric multiple sclerosis (MS) affects up to 10% of MS patients before age 18.
- Recent studies highlight numerous genetic and environmental risk factors for pediatric MS.
- Understanding these factors is crucial for elucidating MS pathophysiology in children.
Purpose of the Study:
- To review epidemiologic factors in the pathogenesis of pediatric MS.
- To discuss clinical features, diagnosis, and differential diagnosis.
- To outline treatment approaches and prognosis for pediatric MS.
Main Methods:
- Literature review of recent international and collaborative studies.
- Synthesis of research on genetic and environmental risk factors.
- Analysis of clinical presentation and management strategies.
Main Results:
- Identification of an increasing number of genetic and environmental risk factors.
- Improved understanding of pediatric MS pathophysiology.
- Emphasis on management of relapses and chronic symptoms for better outcomes.
Conclusions:
- Ongoing research focuses on pathobiology, treatment efficacy, and long-term prognosis.
- Cognitive development and academic potential are key areas for future study.
- Collaborative, multinational efforts are essential for optimizing care for pediatric MS.
Purpose Of Review:
This review discusses the epidemiologic factors involved in the pathogenesis of pediatric multiple sclerosis (MS), which have been the focus of numerous studies in the last several years. We also review the clinical features (including diagnostic evaluation and differential diagnosis) of, treatment approach to, and prognosis of pediatric MS.
Recent Findings:
Up to 10% of patients with MS have their initial demyelinating before the age of 18 years. Over the past 15 years, international and collaborative studies have identified an increasing number of genetic and environmental risk factors for pediatric MS. Identification of these risks and their interplay allow for better understanding of the pathophysiology of pediatric MS, which may inform subsequent treatment and disease management. Careful attention to the management of relapses and chronic symptoms, including implementation of lifestyle modifications and pharmacologic interventions, enables improved school performance and quality of life.
Summary:
Ongoing research in the field of pediatric MS aims to better understand the epidemiologic factors involved in the pathobiology, safety and efficacy of disease-modifying treatments, and long-term prognosis, particularly of cognitive development and academic potential. Collaborative, multinational studies will enable the advancements needed to truly optimize clinical care for this population.
Related Concept Videos
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption